SE0202240D0 - Genes - Google Patents

Genes

Info

Publication number
SE0202240D0
SE0202240D0 SE0202240A SE0202240A SE0202240D0 SE 0202240 D0 SE0202240 D0 SE 0202240D0 SE 0202240 A SE0202240 A SE 0202240A SE 0202240 A SE0202240 A SE 0202240A SE 0202240 D0 SE0202240 D0 SE 0202240D0
Authority
SE
Sweden
Prior art keywords
identification
genes
cb1b
psychiatric
obesity
Prior art date
Application number
SE0202240A
Other languages
English (en)
Inventor
Huy Khang Vu
Thierry Groblewski
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202240A priority Critical patent/SE0202240D0/sv
Publication of SE0202240D0 publication Critical patent/SE0202240D0/sv
Priority to US10/521,428 priority patent/US20060115816A1/en
Priority to PCT/GB2003/003067 priority patent/WO2004007551A1/en
Priority to AU2003254457A priority patent/AU2003254457A1/en
Priority to EP03764008A priority patent/EP1525220A1/en
Priority to US11/622,220 priority patent/US20070117138A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE0202240A 2002-07-17 2002-07-17 Genes SE0202240D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0202240A SE0202240D0 (sv) 2002-07-17 2002-07-17 Genes
US10/521,428 US20060115816A1 (en) 2002-07-17 2003-07-14 Splice variant cannabinoid receptor (cb1b)
PCT/GB2003/003067 WO2004007551A1 (en) 2002-07-17 2003-07-14 Splice variant cannabinoid receptor (cb1b)
AU2003254457A AU2003254457A1 (en) 2002-07-17 2003-07-14 Splice variant cannabinoid receptor (cb1b)
EP03764008A EP1525220A1 (en) 2002-07-17 2003-07-14 Splice variant cannabinoid receptor (cb1b)
US11/622,220 US20070117138A1 (en) 2002-07-17 2007-01-11 Splice variant cannabinoid receptor (cb1b)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202240A SE0202240D0 (sv) 2002-07-17 2002-07-17 Genes

Publications (1)

Publication Number Publication Date
SE0202240D0 true SE0202240D0 (sv) 2002-07-17

Family

ID=20288560

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202240A SE0202240D0 (sv) 2002-07-17 2002-07-17 Genes

Country Status (5)

Country Link
US (2) US20060115816A1 (sv)
EP (1) EP1525220A1 (sv)
AU (1) AU2003254457A1 (sv)
SE (1) SE0202240D0 (sv)
WO (1) WO2004007551A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
GB0904795D0 (en) * 2009-03-20 2009-05-06 Univ Leuven Kath Reporter gene constructs for PET
EP2722669A1 (de) 2012-10-22 2014-04-23 Securetec Detektions-Systeme AG Verfahren und Vorrichtung zum Nachweis von illegalen Drogen
WO2019060316A1 (en) * 2017-09-19 2019-03-28 Cannametrix, Llc CELL-BASED DETERMINATION FOR QUANTIFYING THE POWER AND EFFICACY OF CANNABINOIDS AND / OR TERPENOIDS, AND METHODS OF USE THEREOF
CN108546285B (zh) * 2018-03-07 2021-10-26 武汉轻工大学 一种抗癌生物活性肽CB1a及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002640A1 (en) * 1990-08-08 1992-02-20 The United States Of America, Represented By The Secretary, United States Department Of Commerce Cannabinoid receptor
NZ521158A (en) * 2000-04-07 2004-08-27 Arena Pharm Inc Non-endogenous, constitutively activated known G protein-coupled receptors

Also Published As

Publication number Publication date
US20060115816A1 (en) 2006-06-01
AU2003254457A1 (en) 2004-02-02
WO2004007551A1 (en) 2004-01-22
US20070117138A1 (en) 2007-05-24
EP1525220A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
GB0223040D0 (en) Therapeutic compounds
GB0108592D0 (en) Therapeutic agents
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
PL367142A1 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
NO952309D0 (no) Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer
AU2002361811A8 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2001055107A3 (en) Aromatic amines and amides acting on the melanocortin receptors
WO2002079235A3 (en) Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
TR200800691T2 (tr) Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
PT1187832E (pt) Amino heterociclos uteis como agentes farmaceuticos
PL376894A1 (pl) Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych
SE0202240D0 (sv) Genes
PL376895A1 (pl) Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych
NO20005757L (no) Cabergolin og pramipexol - nye anvendelser og kombinasjoner
EA200200063A1 (ru) Химера il6ril6 для лечения нейродегенеративных заболеваний
TW200503717A (en) Substituted 1,4-pyrazine derivatives
DE69728570D1 (de) Thermischer nasaler dilatator
DE60228988D1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
TW200617176A (en) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
NO20025760D0 (no) S-metyl-dihydro-ziprasidon for behandling av psykiatriske og okkul¶re forstyrrelser
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet